ASH 2015 - Multiple Myeloma

Researchers presented data relating to the management of infusion-related reactions (IRRs) associated with single-agent daratumumab treatment in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in the open-label, multicenter, phase 2 Sirius study.

Patient Preferences on Treatment Attributes in MM

Conference Correspondent

Researchers reported results of an online survey that examined the preferences of patients with multiple myeloma (MM) on route of administration and individual treatment-related adverse events.

The Relevance of Minimal Residual Disease Monitoring in Elderly Multiple Myeloma Patients

ASH 2015 - Multiple Myeloma

Conference Correspondent

Researchers reported on a study that assessed the clinical utility of minimal residual disease (MRD) monitoring in elderly patients with multiple myeloma (MM) included in the PETHEMA/GEM2010MAS65 trial.

Final OS Analysis of Panorama 1 Trial of Panobinostat/Bortezomib/Dexamethasone in RRMM

ASH 2015 - Multiple Myeloma

Conference Correspondent

Researchers present the final data for the secondary end point of overall survival across the entire study population of the phase 3 clinical trial PANORAMA 1, which evaluated panobinostat in combination with bortezomib and dexamethasone. Overall survival was not statistically significant.

Bortezomib/Melphalan/Prednisolone Induction Therapy Followed by Lenalidomide/Dexamethasone Consolidation and Lenalidomide Maintenance in Transplant-Ineligible Patients with Newly Diagnosed MM

ASH 2015 - Multiple Myeloma

Conference Correspondent

The VISTA study demonstrated good tolerability of VMP; however, in a subsequent phase 2 trial, there was a higher rate of treatment discontinuation than expected. In this study, investigators demonstrated lowering the intensity of VMP proved to be both safe and effective for newly diagnosed multiple myeloma (NDMM).